by Eric Christianson | Apr 12, 2023 | Endocrine Medication and Disease State Clinical Pearls
It is theorized that patients who are taking a GLP-1 agonist are at a greater risk for pancreatitis due to the medication causing an increase in stimulation of GLP-1 receptors located in the pancreas. This could lead to an overgrowth or overactivation of pancreatic...
by Eric Christianson | Mar 19, 2023 | Endocrine Medication and Disease State Clinical Pearls
Tirzepatide is a newer medication that is likely to get significant use in Type 2 diabetes and weight management. With the help of a wonderful pharmacy student, we previously did a tirzepatide clinical breakdown which you can find here. Tirzepatide avoids many drug...
by Eric Christianson | Mar 8, 2023 | Endocrine Medication and Disease State Clinical Pearls
I know some folks out there really like crossword puzzles, so I figured why not combine a little fun with a little pharmacology education? I’ve created a free pharmacology crossword puzzle that you should be able to work through below. I didn’t make it...
by Eric Christianson | Jan 8, 2023 | Clinical Guideline Updates For Pharmacists
The ADA has released its 2023 guidelines. There are a significant number of impacts on medication therapy, and in this post I will outline my most important takeaways. I was also recently catching up with my friend and fellow pharmacist, Derek Borkowski who is the...
by Eric Christianson | Sep 7, 2022 | Endocrine Medication and Disease State Clinical Pearls
Drug interactions don’t come to the top of my mind when I see GLP-1 agonists in use. We are fortunate that they do not have a lot of significant interactions, but I don’t think you should forget about them altogether. I’ve provided a list below of my...
